Ticker brief · 2026-10-18

LQDA LIQUIDIA CORP

Settlement preserves commercialization, but label restrictions divide the recovery trade

Consumer, Non-cyclical · Biotechnology

Lean: mixed
last close
$42.65
1 day
+7.5%
14 days
+55.8%
mkt cap
$7.0B
signals 14d
166
authors 14d
72
crowd 14d
-1.4σ

LQDA has a mixed narrative with a bullish settlement consensus, but institutional ownership reports establish participation rather than a decisive smart-money endorsement. The late-week shift is from celebrating legal resolution to debating restricted off-label access and pipeline patent exposure, even as H.C. Wainwright raises its target to $65 from $58. Disclosed calls and profit-taking frame an event-driven recovery trade; the current book's 2026-10-14 LONG returned -4.74%, contradicting claims that settlement relief automatically produces sustained upside.

BULL CAMP10 claims

Settlement preserves YUTREPIA commercialization and removes the immediate product-removal threat. Bulls argue the valuation damage exceeds settlement costs, existing cash limits dilution risk, and off-label prescribing or L606 development can restore upside.

Key voices
@DeepValuePlayMEDIUM-HIGHB-2.26@PharmdcaMEDIUM-HIGHC-3.41@semodoughMEDIUM-HIGHC-1.06@PersimmonTIMEDIUM-HIGHA+0.79@SpecialSitsNewsHIGHB-2.08
“Contrasts $3.6B of lost value with a $380.7M settlement, framing the 9.5x disparity as excessive punishment.”— @Pharmdca ·
BEAR / SKEPTIC4 claims

Preserving PAH access does not restore unrestricted commercial opportunity: narrower labeling, contested off-label use and unresolved pipeline patent questions constrain the recovery. Financing skeptics separately argue settlement obligations could require new capital.

Key voices
@Biotech2k1MEDIUM-HIGHA+1.11@BiomavenMEDIUM-HIGHA-0.63@Quantumup1MEDIUMC+0.10@FiercePharmaMEDIUM-HIGHB+0.46@RevSharkHIGHB+1.92
“Expects severe off-label restrictions to favor UTHR while Liquidia's next-generation drug remains in trials.”— @Biomaven ·
Hypotheses15direction · basis · magnitude · supporters — NEW = first seen this week
▲Liquidia's global settlement resolves six lawsuits and preserves YUTREPIA commercialization, removing the immediate threat of product withdrawal.
bullcatalystlarge if true~5d horizon+55.8% since 2026-10-09
@Omnitrader69LOW-MEDIUMC-2.174s@PharmdcaMEDIUM-HIGHC-3.413s@semodoughMEDIUM-HIGHC-1.062s@zohmbasticMEDIUMC-2.941s@AlertsAndNewsLOW-MEDIUMC-3.921s@BriefingcomB-2.261s+22 more
▲Preserved commercialization and future revenue make Liquidia undervalued after its legal selloff, supporting a substantial recovery in equity value.
bullfundamentallarge if true~40d horizonNEW+59.1% since 2026-10-13
@DeepValuePlayMEDIUM-HIGHB-2.263s@PharmdcaMEDIUM-HIGHC-3.412s@Omnitrader69LOW-MEDIUMC-2.171s@MitchMartan98MEDIUMC-3.791s@Pablo01618LOW-MEDIUMA-0.561s · insight@jimmyhuliMEDIUMC-2.251s+1 more
▲Off-label ILD prescribing can continue despite the settlement, preserving commercial upside beyond YUTREPIA's explicitly protected PAH market.
bullfundamentallarge if true~30d horizonNEWthin⚠ single-author+59.1% since 2026-10-13
@DeepValuePlayMEDIUM-HIGHB-2.262s@BiomavenMEDIUM-HIGHA-0.631s · insight
▼Narrower labeling and severe off-label restrictions constrain Liquidia's addressable market, leaving the settlement commercially favorable to United Therapeutics.
bearfundamentallarge if true~30d horizon+55.8% since 2026-10-10
@BiomavenMEDIUM-HIGHA-0.632s · insight@BriefingcomB-2.261s@BPharmCatalystMEDIUM-HIGHC1s@fwpharmaMEDIUM-HIGHB-1.911s@FiercePharmaMEDIUM-HIGHB+0.461s@BioStocksMEDIUM-HIGHC-1.771s
▼Dependence on YUTREPIA and unresolved chemistry or patent vulnerabilities leave Liquidia exposed, with additional risks extending into future pulmonary indications.
bearfundamentallarge if true~40d horizonNEW⚠ single-author+59.1% since 2026-10-13
@Biotech2k1MEDIUM-HIGHA+1.117s · insight@DeepValuePlayMEDIUM-HIGHB-2.261s
▼Liquidia may need additional financing to meet settlement obligations to United Therapeutics, creating capital-raising pressure despite favorable legal resolution.
bearmechanicsmedium if true~15d horizonNEWthin⚠ single-author+59.1% since 2026-10-13
@Quantumup1MEDIUMC+0.103s
▲Liquidia's existing cash and capital allocation can support development without additional financing, reducing concerns about shareholder dilution after settlement.
bullmechanicsmedium if true~20d horizonNEWthin⚠ single-author+59.1% since 2026-10-13
@semodoughMEDIUM-HIGHC-1.061s@DeepValuePlayMEDIUM-HIGHB-2.261s
▲L606 development and alternative regulatory strategies preserve future indication expansion, providing Liquidia commercial optionality beyond the settlement's immediate market access.
bullfundamentallarge if true~40d horizonNEWintensifying⚠ single-author+59.1% since 2026-10-13
@semodoughMEDIUM-HIGHC-1.061s@DeepValuePlayMEDIUM-HIGHB-2.264s
▲Liquidia's request for expedited FDA approval of an NDA supplement creates a specific regulatory avenue in its response to litigation.
bullcatalystmedium if true~10d horizonthin⚠ single-author+55.8% since 2026-10-09
@Omnitrader69LOW-MEDIUMC-2.171s
▲BTIG's upgrade to Buy from Neutral with a $70 target provides a discrete sell-side endorsement of Liquidia's post-settlement recovery.
bullcatalystmedium if true~5d horizonNEWintensifying+25.7% since 2026-10-14
@Quantumup1MEDIUMC+0.101s@zohmbasticMEDIUMC-2.941s@BriefingcomB-2.261s@BioStocksMEDIUM-HIGHC-1.771s@ScalpIdeasLOW-MEDIUMC1s
▲LifeSci's upgrade to Outperform with a $59 target recognizes settlement-driven legal relief as a positive change in Liquidia's investment case.
bullcatalystmedium if true~5d horizonNEWthin⚠ single-author+25.7% since 2026-10-14
@semodoughMEDIUM-HIGHC-1.061s@sp3cul8rMEDIUM-HIGHB-1.311s · insight
▲H.C. Wainwright's target increase to $65 from $58 and reiterated Buy extend positive sell-side reassessment after Liquidia's legal settlement.
bullcatalystsmall if true~5d horizonNEWthin⚠ single-author+22.6% since 2026-10-15
@Quantumup1MEDIUMC+0.101s
▼Large losses on Liquidia positions may trigger fund redemptions and forced asset sales, prolonging selling pressure after the initial collapse.
bearpositioningmedium if true~15d horizonthin⚠ single-author+55.8% since 2026-10-09
@RevSharkHIGHB+1.921s · insight
◆Investors can trim Liquidia exposure after the rebound and wait for another entry while retaining a constructive longer-term view.
neutralpositioningsmall if true~10d horizonNEWthin⚠ single-author+59.1% since 2026-10-13
@shufen46250836MEDIUM-HIGHB+0.452s · insight
▲Reported institutional accumulation and downside-underwriting options activity suggest investor support for Liquidia despite the adverse legal repricing.
bullpositioningmedium if true~15d horizonthin⚠ single-author+55.8% since 2026-10-10
@tenet_researchMEDIUM-HIGHC-1.231s@tsungrowMEDIUMC-0.471s
Direct calls4authors taking explicit directional positions
@MitchMartan98MEDIUMC-3.79
Expects LQDA above $60, with substantial upside remaining from $37.50.
@shufen46250836MEDIUM-HIGHB+0.45
Plans further selling of LQDA holdings and will wait for another buying opportunity despite longer-term optimism.
@Braden_Hoffman_LOW-MEDIUMC+0.23
Considers entering near-term speculative LQDA calls after perceived legal resolution.
@Biotech2k1MEDIUM-HIGHA+1.11
One signal proposes buying ahead of clinical data, but its unspecified stock reference conflicts with the author's otherwise bearish LQDA commentary.
Sellside activity8
BTIG upgrade PT 70Upgraded to Buy from Neutral.
via @Quantumup1
BTIG upgrade PT 70Relayed the Buy upgrade after settlement; repeats the same firm action reported by other authors.
via @zohmbastic
BTIG upgrade PT 70Upgraded to Buy from Neutral; duplicate relay of the same action.
via @Briefingcom
BTIG upgrade PT 70Reported the Buy upgrade; duplicate relay of the same action.
via @BioStocks
BTIG upgrade PT 70Reported the Buy upgrade; duplicate relay of the same action.
via @ScalpIdeas
LifeSci upgrade PT 59Upgraded to Outperform after settlement removed litigation risk.
via @semodough
LifeSci upgradeRelayed the post-settlement upgrade without specifying a target; repeats the LifeSci action.
via @sp3cul8r
H.C. Wainwright pt_raise PT 65 (from 58)Raised the target and reiterated Buy after the legal settlement.
via @Quantumup1
News / data points5discrete events + data quoted by authors
@semodoughMEDIUM-HIGHC-1.06
Settlement resolves six lawsuits, preserves YUTREPIA access and specifies $380.7M payments alongside Q3 sales information.
2026-10-13+59.1% since
@PharmdcaMEDIUM-HIGHC-3.41
Compares a $3.6B valuation loss with the $380.7M settlement, identifying a 9.5x disparity.
2026-10-13+59.1% since
@BiomavenMEDIUM-HIGHA-0.63
Expects severely restricted off-label use to benefit UTHR while LQDA's next-generation drug remains in trials.
2026-10-14+25.7% since
@Quantumup1MEDIUMC+0.10
H.C. Wainwright raises its target to $65 from $58 and reiterates Buy following settlement.
2026-10-15+22.6% since
@tenet_researchMEDIUM-HIGHC-1.23
Reports increased institutional ownership, additional fund participation and $5.8B total investment.
2026-10-14+25.7% since
Position disclosures3skin in the game
@shufen46250836MEDIUM-HIGHB+0.45
Discloses trimming LQDA and subsequently plans additional selling while retaining longer-term optimism.
@zohmbasticMEDIUMC-2.94
Discloses existing LQDA calls; subsequently reports trimming a 30 call after its premium reached 8.40.
@davydaytradesLOW-MEDIUMC-0.53
Discloses holding LQDA in anticipation of a large profit.
Desk readconvergence assessment
Agreement is strongest on preserved commercialization, not on restored growth: Biomaven first anticipated off-label prescribing, then narrowed that assessment to PAH and warned of severe restrictions. Both camps contain MEDIUM-HIGH voices, so there is no clean credibility advantage; bullish anchors DeepValuePlay and Pharmdca have negative trader_score_20 values of -2.26 and -4.23, while bearish Biotech2k1 is also negative at -0.97 and financing skeptic Quantumup1 is positive at 1.13. Actual off-label access, financing terms and pipeline patent clarity would change the balance; the current book's -4.74% return challenges automatic-rebound claims, and the prior hypotheses remain unscored.
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d70% cheap · 1 pctile own 1yIV/HV 0.41×
Skew — 25Δ RR 30d-0.030 95 pctile own 1ycalls bid vs puts (call skew rich)
Net dealer OI (NDOI)+10.18 elevated5-session Δ -0.45 (as of 2026-07-16)
OI alarmquietlast alarm 2026-04-21 (z=2.2)
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-15 · now -0.03 (−1 bearish … +1 bullish)
Who spoke72
authorgradetrader scoresignalsmean sent
@DeepValuePlayB-2.2632+0.15
@Biotech2k1A+1.1110-0.44
@Omnitrader69C-2.179+0.38
@PharmdcaC-3.417+0.39
@zohmbasticC-2.945+0.35
@semodoughC-1.065+0.35
@Quantumup1C+0.105-0.03
@RevSharkB+1.924-0.52
@MitchMartan98C-3.794+0.67
@shufen46250836B+0.453+0.03
@OptionsFlowBossC·3+0.23
@tenet_researchC-1.233+0.30
@BiomavenA-0.633-0.00
@AlertsAndNewsC-3.923+0.23
@BriefingcomB-2.263+0.33
@TickeronC+1.532-0.38
@MartinShkreliB+0.882+0.72
@OracleNYSEC+0.832+0.23
@HedgeFundTipsB+0.732+0.15
@BioStocksC-1.772-0.08
@snorlax_uwC·2+0.20
@OpenOutcrierC·2+0.50
@SpartanTradingC+1.302+0.20
@MrStockLockPro1C-2.142+0.22
@sp3cul8rB-1.312+0.40
Recent signals30of 166 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-15@Biotech2k1-0.60The author reiterates that patent warnings against LQDA were correct.+22.6%
2026-10-15@Biotech2k1-0.65The author says LQDA faces compounded risk in IPF and PPF indications.+22.6%
2026-10-15@Biotech2k1-0.70The author lost confidence in LQDA's patent position and views INSM's prodrug design as more defensible.+22.6%
2026-10-15@Biotech2k1-0.65The author reiterates warnings about LQDA's dependence on one drug.+22.6%
2026-10-15@Biotech2k1-0.70The author says LQDA's value depended entirely on Yutrepia, unlike a diversified competitor.+22.6%
2026-10-15@Biotech2k1-0.50The author says prior due diligence justified avoiding LQDA.+22.6%
2026-10-15@Biotech2k1+0.65Buy and ride the stock higher when clinical data arrives. — The author states an intention to buy and ride the stock higher on upcoming data.+22.6%
2026-10-15@DeepValuePlay+0.35Believes ILD research remains a viable option for Liquidia.+22.6%
2026-10-15@DeepValuePlay+0.30Views a regulatory-path strategy as an option that could pressure a competitor.+22.6%
2026-10-15@DeepValuePlay+0.60Views additional studies and potential royalty flexibility as worthwhile for Liquidia.+22.6%
2026-10-15@DeepValuePlay+0.60Argues Liquidia's regulatory strategy could avoid a 30-month stay and preserve judicial flexibility.+22.6%
2026-10-15@Biotech2k1-0.60The author says chemistry and patent concerns were reasons not to own LQDA.+22.6%
2026-10-15@Biotech2k1-0.30Argues INSM's TPIP is patent-distinct and could generate over $5B despite rivals' doubts.+22.6%
2026-10-15@sp3cul8r+0.40Reports supportive analyst actions following a favorable patent settlement.+22.6%
2026-10-15@Biotech2k1-0.30Dismisses LQDA bulls' concerns and expresses confidence in INSM.+22.6%
2026-10-15@nanalyzetweets+0.20Reports a $381 million settlement ending six lawsuits while keeping LQDA's YUTREPIA on market.+22.6%
2026-10-15@MrStockLockPro1+0.45Recaps four completed entry-to-high gains from the prior watchlist.+22.6%
2026-10-15@snorlax_uw+0.00Lists five sell-side rating actions and price targets.+22.6%
2026-10-15@OptionsFlowBoss+0.00Shares LQDA open-interest changes without a textual directional interpretation.+22.6%
2026-10-15@matt2cents+0.50Reports capacity expansion, a favorable lawsuit settlement, and a large drone-battery order.+22.6%
2026-10-15@Quantumup1+0.40H.C. Wainwright raised Liquidia's target to $65 from $58 and reiterated Buy after a legal settlement.+22.6%
2026-10-14@DeepValuePlay+0.60States an author fair-value estimate of $50 versus a $45 share price.+25.7%
2026-10-14@DeepValuePlay+0.45Builds a bullish annualized revenue and EBITDA valuation scenario for Liquidia.+25.7%
2026-10-14@SpartanTrading+0.40Recaps completed long equity ideas and point gains.+25.7%
2026-10-14@joinautopilot+0.20Market recap covering downgrade, credit stress, fine, investment and lawsuit settlement.+25.7%
2026-10-14@financespotnews+0.20Reports LQDA surged following a settlement announcement.+25.7%
2026-10-14@Omnitrader69+0.20Discloses a TDIC trade and an INFQ add while commenting that LQDA failed to bounce on good news.+25.7%
2026-10-14@StockSwingAlert+0.50Praises another user's prior LQDA call without a new forward view.+25.7%
2026-10-14@tenet_research+0.30Reports increased institutional ownership, fund additions and $5.8B total investment.+25.7%
2026-10-14@ElliottWaveSage+0.20Liquidia agreed to pay $380.7M to settle six lawsuits while retaining YUTREPI availability.+25.7%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.